1. Cortical morphology predicts placebo response in multiple sclerosis
- Author
-
Mariya V. Cherkasova, Jessie F. Fu, Michael Jarrett, Poljanka Johnson, Shawna Abel, Roger Tam, Alexander Rauscher, Vesna Sossi, Shannon Kolind, David K. B. Li, A. Dessa Sadovnick, Lindsay Machan, J. Marc Girard, Francois Emond, Reza Vosoughi, Anthony Traboulsee, and A. Jon Stoessl
- Subjects
Medicine ,Science - Abstract
Abstract Despite significant insights into the neural mechanisms of acute placebo responses, less is known about longer-term placebo responses, such as those seen in clinical trials, or their interactions with brain disease. We examined brain correlates of placebo responses in a randomized trial of a then controversial and now disproved endovascular treatment for multiple sclerosis. Patients received either balloon or sham extracranial venoplasty and were followed for 48 weeks. Venoplasty had no therapeutic effect, but a subset of both venoplasty- and sham-treated patients reported a transient improvement in health-related quality of life, suggesting a placebo response. Placebo responders did not differ from non-responders in total MRI T2 lesion load, count or location, nor were there differences in normalized brain volume, regional grey or white matter volume or cortical thickness (CT). However, responders had higher lesion activity. Graph theoretical analysis of CT covariance showed that non-responders had a more small-world-like CT architecture. In non-responders, lesion load was inversely associated with CT in somatosensory, motor and association areas, precuneus, and insula, primarily in the right hemisphere. In responders, lesion load was unrelated to CT. The neuropathological process in MS may produce in some a cortical configuration less capable of generating sustained placebo responses.
- Published
- 2022
- Full Text
- View/download PDF